AU2019251360B2 - Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways - Google Patents

Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways Download PDF

Info

Publication number
AU2019251360B2
AU2019251360B2 AU2019251360A AU2019251360A AU2019251360B2 AU 2019251360 B2 AU2019251360 B2 AU 2019251360B2 AU 2019251360 A AU2019251360 A AU 2019251360A AU 2019251360 A AU2019251360 A AU 2019251360A AU 2019251360 B2 AU2019251360 B2 AU 2019251360B2
Authority
AU
Australia
Prior art keywords
amine
sulfonyl
pyrimidin
4alkyl
morpholinophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019251360A
Other languages
English (en)
Other versions
AU2019251360A1 (en
Inventor
Emily M. Stocking
Wolfgang J. Wrasidlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuropore Therapies Inc
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of AU2019251360A1 publication Critical patent/AU2019251360A1/en
Application granted granted Critical
Publication of AU2019251360B2 publication Critical patent/AU2019251360B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2019251360A 2018-04-10 2019-04-09 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways Active AU2019251360B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655741P 2018-04-10 2018-04-10
US62/655,741 2018-04-10
PCT/US2019/026634 WO2019199864A1 (en) 2018-04-10 2019-04-09 Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways

Publications (2)

Publication Number Publication Date
AU2019251360A1 AU2019251360A1 (en) 2020-10-08
AU2019251360B2 true AU2019251360B2 (en) 2025-03-13

Family

ID=66248833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019251360A Active AU2019251360B2 (en) 2018-04-10 2019-04-09 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways

Country Status (11)

Country Link
US (3) US11492348B2 (https=)
EP (1) EP3774783B1 (https=)
JP (1) JP7369139B2 (https=)
KR (1) KR102803762B1 (https=)
CN (1) CN112189012B (https=)
AU (1) AU2019251360B2 (https=)
EA (1) EA202092444A1 (https=)
ES (1) ES3032793T3 (https=)
MX (1) MX2020010576A (https=)
SG (1) SG11202008832TA (https=)
WO (1) WO2019199864A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3032793T3 (en) 2018-04-10 2025-07-24 Neuropore Therapies Inc Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
MX2021013662A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
IL325201A (en) 2019-06-17 2026-02-01 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of using them
CN113121499B (zh) * 2021-04-13 2022-05-31 海南锦瑞制药有限公司 奥美拉唑的合成方法及应用
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2009150230A1 (en) * 2008-06-13 2009-12-17 Novartis Ag 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
WO2010052569A2 (en) * 2008-11-10 2010-05-14 University Of Basel Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
WO2012122383A2 (en) * 2011-03-09 2012-09-13 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
WO2015162084A1 (en) * 2014-04-22 2015-10-29 Universitaet Basel Novel manufacturing process for triazine, pyrimidine and pyridine derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070740A1 (en) 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2475375A4 (en) 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
AU2015366357B2 (en) 2014-12-17 2018-07-19 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof
DK3416957T3 (da) 2016-02-19 2020-09-21 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
CN112533917B (zh) 2018-04-10 2024-06-21 神经孔疗法股份有限公司 作为vps34的抑制剂的吗啉衍生物
ES3032793T3 (en) * 2018-04-10 2025-07-24 Neuropore Therapies Inc Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084786A1 (en) * 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2009150230A1 (en) * 2008-06-13 2009-12-17 Novartis Ag 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
WO2010052569A2 (en) * 2008-11-10 2010-05-14 University Of Basel Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
WO2012122383A2 (en) * 2011-03-09 2012-09-13 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
WO2015162084A1 (en) * 2014-04-22 2015-10-29 Universitaet Basel Novel manufacturing process for triazine, pyrimidine and pyridine derivatives

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number: 300706-72-3; STN Entry Date: 01 November 2000; 4-(4,4''-diethoxy[1,1':3',1''-terphenyl]-5'-yl)-morpholine. *
CAS Registry Number: 301171-51-7; STN Entry date: 03 November 2000; 4-[4,6-bis(4-methoxyphenyl)-2-pyridinyl]-morpholine. *
CAS Registry Number: 858850-19-8; STN Entry Date: 08 August 2005; 1-(3,5-di-p-tolylphenyl)-piperidine. *
CAS Registry Number: STN Entry Date: *
KATRITZKY, A.R.; ET Al.; "Benzotriazole-assisted preparations of 2-(substituted amino)pyridines and 2-pyridones", Journal of Organic Chemistry, 1997, Vol. 62(18), pages 6210-6214. *
KATRITZKY, A.R.; ET Al.; "Syntheses of 2-Alkylamino- and 2-Dialkylamino-4,6-diarylpyridines and 2,4,6-Trisubstituted Pyrimidines Using Solid-Phase-Bound Chalcones", Journal of Combinatorial Chemistry, 2000, Vol. 2(2), Pages 182-185. *
MEREDITH, E.L.; ET AL.; "Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D, Journal of Medicinal Chemistry, 2010, Vol. 53(15), pages 5422-5438. *
NALINI.; ET AL.; Molecular Diversity, 2018, published 23 October 2017, Vol. 22(1), pages 47-56 and Supplementary Information pages 1-15. *
REDDY, K. R., ET AL.; "Cycloaromatization of methyl (E)-4-lithio-3-(1-pyrrolidinyl)-2-butenoate with α-oxoketene N,S-acetals: Direct synthesis of 3,5-bis(cycloalkylamino)biphenyls", Synthesis, 1995, Vol. 8, Pages 929-930. *

Also Published As

Publication number Publication date
AU2019251360A1 (en) 2020-10-08
US11492348B2 (en) 2022-11-08
US20230265086A1 (en) 2023-08-24
KR102803762B1 (ko) 2025-05-09
US20240327396A1 (en) 2024-10-03
EP3774783B1 (en) 2025-06-04
SG11202008832TA (en) 2020-10-29
US12049462B2 (en) 2024-07-30
CN112189012A (zh) 2021-01-05
KR20200143709A (ko) 2020-12-24
EP3774783A1 (en) 2021-02-17
EA202092444A1 (ru) 2021-01-26
ES3032793T3 (en) 2025-07-24
MX2020010576A (es) 2021-03-02
CA3094714A1 (en) 2019-10-17
WO2019199864A1 (en) 2019-10-17
US20210163462A1 (en) 2021-06-03
CN112189012B (zh) 2024-02-13
JP2021521178A (ja) 2021-08-26
JP7369139B2 (ja) 2023-10-25

Similar Documents

Publication Publication Date Title
AU2019251360B2 (en) Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
CN112638917B (zh) 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
CN107266455B (zh) 三唑并吡嗪
TWI660946B (zh) 作為ｍａｇｌ抑制劑之胺基甲酸１，１，１－三氟－３－羥基丙烷－２－酯衍生物
CN112707893B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
EP3066104B1 (en) Triazolopyrazine derivatives as brd4 inhibitors
JP6322205B2 (ja) がん治療用のピリミジン−２，４−ジアミン誘導体
JP2023521694A (ja) Ｃｄ３８阻害薬
EP3119760A1 (en) Piperidine-dione derivatives
CA3107365A1 (en) Pyrazine compounds and uses thereof
MX2010013627A (es) Diazacarbazoles y metodos de uso.
WO2023006013A1 (zh) 新型parp7抑制剂及其应用
WO2022155419A1 (en) Indazoles and azaindazoles as lrrk2 inhibitors
CN120535527A (zh) 一类含氮稠环类化合物、制备方法和用途
CA3094714C (en) Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
CA3180661A1 (en) Cycloalkyl pyrimidines as ferroportin inhibitors
EA045787B1 (ru) Тризамещенные арильные и гетероарильные производные как модуляторы киназы pi3 и путей аутофагии
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a
CN118930534A (zh) 含有吲唑的化合物、其药物组合物及其制备方法和用途
OA18588A (en) 1,1,1-Trifluoro-3-Hydroxypropan-2-yl Carbamate Derivatives and 1,1,1-Trifluoro-4Hydroxybutan-2-yl Carbamate Derivatives as Magl Inhibitors.
HK1210169B (en) Triazolopyrazine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)